← Back to Search

Postoperative Antibiotics for Salivary Duct Procedures

Phase 4
Led By Rohan Walvekar, M.D.
Research Sponsored by Our Lady of the Lake Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All adult patients (18 years of age or older) who are undergoing salivary duct surgery and stent placement at Our Lady of the Lake Regional Medical Center
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights

Study Summary

This trial examines the efficacy of postoperative antibiotics following salivary duct stent placement.

Who is the study for?
Adults over 18 needing salivary duct surgery and stent placement at Our Lady of the Lake Regional Medical Center can join. Excluded are those unwilling to be randomized, with acute infections, immunocompromised, early stent dislodgement, or who don't finish their antibiotics unless due to side effects.Check my eligibility
What is being tested?
The trial is testing if taking oral antibiotics (Clindamycin or Augmentin) after salivary duct stent placement is necessary. Patients will either receive postoperative antibiotics for 10-14 days or none, to see if avoiding them reduces complications like gastrointestinal issues and antibiotic resistance.See study design
What are the potential side effects?
Potential side effects from Clindamycin or Augmentin include stomach upset, nausea, diarrhea potentially leading to C.diff infection (a serious gut infection), and contributing to antibiotic resistance.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am an adult scheduled for salivary duct surgery with stent placement.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Communicable Diseases

Trial Design

2Treatment groups
Active Control
Group I: Group B (no Antibiotic)Active Control1 Intervention
Group B will not be given postoperative oral antibiotics upon discharge.
Group II: Group A (Antibiotic)Active Control1 Intervention
Group A will receive postoperative oral antibiotics for 10 - 14 days (Clindamycin or Augmentin) upon discharge.

Find a Location

Who is running the clinical trial?

Louisiana State University Health Sciences Center in New OrleansOTHER
116 Previous Clinical Trials
44,068 Total Patients Enrolled
Our Lady of the Lake HospitalLead Sponsor
12 Previous Clinical Trials
799 Total Patients Enrolled
Rohan Walvekar, M.D.Principal InvestigatorOur Lady of the Lake Hospital
~3 spots leftby Dec 2024